Hims & Hers Health, Inc. (HIMS)

NYSE: HIMS · Real-Time Price · USD
49.78
-9.37 (-15.84%)
At close: Oct 17, 2025, 4:00 PM EDT
50.65
+0.87 (1.75%)
After-hours: Oct 17, 2025, 7:59 PM EDT
-15.84%
Market Cap11.25B
Revenue (ttm)2.01B
Net Income (ttm)193.60M
Shares Out 226.02M
EPS (ttm)0.79
PE Ratio63.11
Forward PE68.49
Dividendn/a
Ex-Dividend Daten/a
Volume74,604,125
Open57.12
Previous Close59.15
Day's Range49.60 - 57.45
52-Week Range18.33 - 72.98
Beta2.25
AnalystsHold
Price Target37.20 (-25.27%)
Earnings DateNov 3, 2025

About HIMS

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supp... [Read more]

Founded 2017
Employees 1,637
Stock Exchange NYSE
Ticker Symbol HIMS
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 11 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price target is $37.2, which is a decrease of -25.27% from the latest price.

Price Target
$37.2
(-25.27% downside)
Analyst Consensus: Hold
Stock Forecasts

News

Why Hims & Hers stock is failing to retain menopause gains and what comes next?

Hims & Hers Health Inc (NYSE: HIMS) started this week on a positive note after announcing its expansion into menopause-related treatments – a large and underserved market. However, the rally is fading...

7 hours ago - Invezz

Hims & Hers Stock's 150% Surge Is All Fundamentals—No Novo, No Problem

Hims & Hers Health Inc. (NYSE:HIMS) has become one of 2025's most surprising winners, up more than 150% year-to-date and over 200% in the past twelve months. But what's making Wall Street sit up this ...

1 day ago - Benzinga

Hims & Hers: Ramping Up A New Billion-Dollar Segment (Rating Upgrade)

I am upgrading Hims & Hers Health, Inc. to a Buy with an $80 price target, implying 30% upside. The new 'Hers' specialty in Menopause is expected to help the company drive over $1B in Hers segment rev...

1 day ago - Seeking Alpha

How HIMS Stock Rises To $120?

Hims & Hers stock (NYSE: HIMS) increased by 16% yesterday following its announcement about expanding into the treatment of menopause and perimenopause—a strategic shift indicating that the company is ...

1 day ago - Forbes

Weight-loss drugs shook up the stock market. Menopause treatments could be next.

Hims & Hers is taking aim at menopause and perimenopause in an attempt to tap in to a huge and potentially highly lucrative market.

2 days ago - Market Watch

Hers Launches Menopause and Perimenopause Specialty, Taking the Next Step Toward $1B of Hers Revenue in 2026

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of a new specialty in women's health, offering access to aff...

2 days ago - Business Wire

Hims & Hers to Offer Treatments for Menopause, Perimenopause

Hims & Hers Health said it is now providing menopause care, marking the company's latest push into hormone-replacement therapies.

2 days ago - WSJ

Hims & Hers to Announce Third Quarter 2025 Financial Results on November 3, 2025

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report third quarter 2025 financial results...

4 days ago - Business Wire

Hims & Hers: Why I'm Betting On HIMS Heading To $100

I see a clear path for Hims & Hers Health to reach $100 a share, and I plan to be there when it gets there. HIMS expects revenue growth to rebound, driven by weight loss and new health offerings, aimi...

4 days ago - Seeking Alpha

How Hims & Hers founder Joe Spector turned 10 failures into $1B idea

Listen and subscribe to The Big Idea with Elizabeth Gore on Apple Podcasts, Spotify, or wherever you find your favorite podcast. How do you break into a tough market and win?

8 days ago - Yahoo Finance

Customers Say Care Through Hims & Hers Matches, or Beats, the Doctor's Office

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today published a new white paper - Understanding Hims & Hers Approach to Clinical Excellence, Quality, and Safety - detailing how...

8 days ago - Business Wire

Hims & Hers Looks To Close $10 ARPU Gap With Product Expansion And Partnerships

Hims & Hers is driving growth through holistic treatment plans, strategic pharma partnerships, and expanded prescription offerings to boost revenue per subscriber. HIMS' recent partnership with Marius...

9 days ago - Seeking Alpha

Berger Montague Investigates Hims & Hers Health Inc. (NYSE: HIMS) Board of Directors for Potential Breaches of Fiduciary Duties

PHILADELPHIA , Oct. 3, 2025 /PRNewswire/ --  Berger Montague , a national securities litigation law firm, advises shareholders of Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) ...

14 days ago - PRNewsWire

Buy HIMS Stock At $56?

Hims & Hers stock (NASDAQ: HIMS) has recently witnessed a remarkable rebound, climbing 42% over the last month from approximately $42 to its current price of $59. This significant increase is primaril...

16 days ago - Forbes

Hims & Hers: Growth Meets FDA Scrutiny And Tariff Risks

Hims & Hers Health, Inc. has shown strong growth, overcoming partnership fallout and posting a 73% year-over-year revenue surge, but faces execution and regulatory risks. HIMS stock's premium valuatio...

21 days ago - Seeking Alpha

Hims & Hers Powers YieldMax's Latest Options-Based Income ETF

YieldMax ETFs grew its expanding lineup of income-oriented funds on Tuesday with the introduction of the YieldMax HIMS Option Income Strategy ETF (NYSE: HIYY).

21 days ago - Benzinga

Hims & Hers Health: Bumpy Ride Will End

Hims & Hers Health has traded very volatile over the last year as the market misunderstand the business opportunity beyond GLP-1s and weight-loss drugs. The online health and wellness faces FDA scruti...

4 weeks ago - Seeking Alpha

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs

The U.S. Food and Drug Administration's recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.

Other symbols: LLYNVOPTHTHNRHEAL
4 weeks ago - Benzinga

Trump Drug Ad Crackdown: FDA Warns Novo Nordisk, Eli Lilly, Hims

The Food and Drug Administration sent warning letters to dozens of drug companies— including popular telehealth firm Hims & Hers and pharmaceutical giants Eli Lilly and Novo Nordisk— demanding they co...

Other symbols: LLYNVO
4 weeks ago - Forbes

FDA Warns Hims Over Ads About Compounded Weight-Loss Drugs

The Food and Drug Administration sent warning letters to dozens of drug companies this month, including popular telehealth firm Hims & Hers, demanding they correct “false or misleading claims” about s...

4 weeks ago - Forbes

Hims & Hers shares drop 6% after FDA warning on semaglutide marketing claims

Hims & Hers Health Inc. (NYSE: HIMS) saw its stock fall 6% on Tuesday following the release of a warning letter from the US Food and Drug Administration (FDA) concerning marketing claims related to it...

4 weeks ago - Invezz

Hims & Hers Scrutinized For Marketing Its Product As Similar To Ozempic, Wegovy

Hims & Hers Health Inc. HIMS stock is trading lower on Tuesday. The U.S. Food and Drug Administration (FDA) issued a warning letter to Hims & Hers Health, dated Sept.

4 weeks ago - Benzinga

US FDA warns Hims & Hers over misleading claims on diabetes, weight-loss drugs

The U.S. Food and Drug Administration has sent a warning letter to telehealth firm Hims & Hers Health regarding its compounded versions of Novo Nordisk's diabetes drug Ozempic and weight-loss treatmen...

4 weeks ago - Reuters

US FDA chief says Super Bowl ad by Hims & Hers 'breached' drug promotion rules

U.S. Food and Drug Administration Commissioner Martin Makary said on Friday that Hims & Hers' Super Bowl advertisement breached federal law as it highlighted the benefits of weight-loss drugs without ...

5 weeks ago - Reuters

Hims & Hers Looks Like Hyper Growth At A Reasonable Price

Hims is now a GARP stock, combining rapid revenue and subscriber growth with a lower, fair valuation after a recent selloff. The company's scalable model, product launches, and global expansion plans ...

5 weeks ago - Seeking Alpha